Catalyst Wire Dossier Catalyst Wire Dossier

Bimekizumab (Bimzelx)

Bimekizumab · UCB Biopharma SRL
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Bimekizumab (Bimzelx), covering 2025-04-10 to 2025-04-10. Get the full timeline:

Most recent: Clinical Trial Update: A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants [Phase 1]

See pricing